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Background: Bladder cancer exists as several distinct subtypes, including urothelial carcinoma (UCa), squamous cell
carcinoma (SCCa), adenocarcinoma and small cell carcinoma. These entities, despite showing distinct morphology
and clinical behavior, arise from the urothelial lining and are often accompanied by similar precursor/in situ
findings. The relationship between these subtypes has not been explored in detail.
Methods: We compared gene expression analysis of the two most common subtypes of bladder cancer, UCa (n =
10) and SCCa (n = 9), with an additional comparison to normal urothelium from non-cancer patients (n = 8) using
Affymetrix GeneChip Human genome arrays (Affymetrix, Santa Clara, CA). The results were stratified by supervised
and unsupervised clustering analysis, as well as by overall fold change in gene expression.
Results: When compared to normal urothelium, UCa showed differential expression of 155 genes using a 5-fold
cut-off. Examples of differentially regulated genes included topoisomerases, cancer-related transcription factors and
cell cycle mediators. A second comparison of normal urothelium to SCCa showed differential expression of 503
genes, many of which were related to squamous-specific morphology (desmosomal complex, intermediate
filaments present within squamous epithelium, squamous cornifying proteins, and molecules upregulated in
squamous carcinomas from other anatomic sites). When compared, 137 genes were commonly dysregulated in
both UCa and SCCa as compared to normal urothelium. All dysregulated genes in UCa were shared in common
with SCCa, with the exception of only 18 genes. Supervised clustering analysis yielded correct classification of
lesions in 26/27 (96%) of cases and unsupervised clustering analysis yielded correct classification in 25/27 (92.6%) of
cases.
Conclusions: The results from this analysis suggest that bladder SCCa shares a significant number of gene
expression changes with conventional UCa, but also demonstrates an additional set of alterations that is unique to
this entity that defines the squamous phenotype. The similarity in deregulated gene products suggests that SCCa
may be a much more closely related entity at the molecular level to conventional UCa than previously
hypothesized.
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Urothelial carcinoma (UCa) represents the most com-
mon form of bladder cancer in the United States (>90%)
and is characterized by frequent mutations in TP53, RB
and PTEN [1]. Morphologically, UCa consists of invasive
nests of carcinoma cells with variable atypia and fre-
quent surrounding retraction artifact (Figure 1A), al-
though this appearance can vary significantly. Less* Correspondence: dhansel@ucsd.edu
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reproduction in any medium, provided the orcommon forms of bladder cancer in the United States
include squamous cell carcinoma (SCCa; Figure 1B),
adenocarcinoma and small cell carcinoma, which are de-
fined as pure morphologic entities that lack a typical
urothelial component [2]. Our understanding of the mo-
lecular relationships between these other forms of blad-
der cancer that arise from the urothelial lining has been
limited and may be based on the low number of cases
available for study and/or lack of significant attention
paid to this topic. It appears, however, that despite a
similar origin from the surface urothelium, these variousLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Two major subtypes of bladder cancer include (A)
urothelial carcinoma, which is the most common form of
bladder cancer and contains variably sized nests and (B)
squamous cell carcinoma, which is characterized by
desmosomes and keratin pearls (arrow).
Hansel et al. BMC Medical Genomics 2013, 6:42 Page 2 of 11
http://www.biomedcentral.com/1755-8794/6/42forms of bladder cancer show differential clinical be-
havior, morphologic appearances, immunohistochemical
markers and response to chemotherapy.
SCCa represents the second most common form of
bladder cancer in the United States (5-8% of bladder can-
cer cases) and is distinguished by invasive squamous car-
cinoma cells containing desmosomes and often keratin
formation [3]. A higher incidence of bladder SCCa has
been reported in parts of the Middle East and Africa, how-
ever, where chronic infection with the water-bourne para-
site Schistosoma haematobium, represents a major risk
factor in the development of this disease [4]. Other poten-
tial risk factors in the development of SCCa include long-
term catheterization, calculi that form in the urinary tract,
and a nonfunctioning bladder, amongst others, and these
risk factors may account for many instances of SCCa iden-
tified in the United States and Europe.
Despite the distinct appearance of UCa and SCCa, the
cellular origin of these two forms of bladder cancer hasbeen debated. Whereas UCa can arise in association
with surface high-grade changes of the urothelium (e.g.,
carcinoma in situ) and SCCa can arise in association
with squamous dysplasia and squamous carcinoma in
situ of the bladder, there are numerous cases that show
overlap of surface changes. For example, SCCa can
occur in the absence of any surface squamous metaplasia
and may only be associated with urothelial carcinoma in
situ [3]. Furthermore, UCa itself has been shown to
demonstrate “divergent” differentiation with the ability
of UCa tumor cells to develop squamous or glandular
features. These findings suggest that 1) the molecular re-
lationship between historically distinct subtypes of blad-
der cancer may be more similar than previously
hypothesized and 2) the surface urothelium in a bladder
undergoing neoplastic alterations may be unusually
suited to give rise to divergent phenotypes in the setting
of both in situ and invasive disease.
To date, much of the molecular analysis on bladder
SCCa has been limited due to a predominant focus on
infectious, Schistosomal-derived cases as well as use of
immortalized bladder cancer cell lines in a number of
studies [5-8]. In this setting, the understanding of the
relationship between UCa and SCCa, as well as the dis-
tinction between primary molecular changes and those
secondarily induced by infection-specific responses, be-
comes difficult. We sought to compare the two most
common forms of pure bladder cancer in the US (UCa
and non-infectious SCCa) using multi-level gene expres-
sion analysis to determine the relationship and possible
hierarchy of these two examples of bladder cancer. The
results from our study suggest a closer relationship be-
tween these neoplastic entities than previously proposed;
a shared evolution of these cancers may represent an op-
portunity for targeting bladder cancer along common
pathways early in the disease process.
Methods
Specimen collection
Specimens were collected with Institutional Review
Board approval. The existing bladder cancer biobank
(1971 onwards) was searched for snap-frozen tissue
obtained from non-neoplastic bladder and/or ureter and
from patients with either UCa or SCCa. Frozen sections
were obtained from all specimens and reviewed; speci-
mens with any necrosis or <90% tumor or normal cell
nuclei were excluded from analysis. H&E slides corre-
sponding to the initial pathology specimen associated
with each sample were re-reviewed for accuracy of
tumor classification. The clinical records for any patients
with normal urothelium were reviewed; any patient with
a precedent or subsequent occurrence of urinary tract
neoplasia was excluded from analysis. This resulted in 8
normal urothelium specimens, 10 UCa specimens and 9
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patient with SCCa had a precedent or concurrent history
of Schistosomal infection. This study was approved by
the Cleveland Clinic IRB.
Raw gene expression levels
Ten micrograms of total RNA from each sample was
processed using the Affymetrix GeneChip one-cycle target
labeling kit (Affymetrix, Santa Clara, CA). The resultant
biotinylated cDNA was fragmented and subsequently
hybridized to the GeneChip Human genome (54,675 probe
sets including more than 35,000 human genes; Affymetrix).
Arrays were washed, stained, and scanned using the
AffymetrixModel450 Fluidics Station and AffymetrixModel
3000 scanner per manufacturer’s recommended protocols.
Expression values were generated using Microarray
Suite (MAS) v5.0 software (Affymetrix). The probes were
redefined according to a new study (http://brainarray.
mhri.med.umich.edu/Brainarray/Database/CustomCDF/
version10) to combine probes representing the same gene
for a single profile per gene. The hybridizations were nor-
malized using the robust multichip averaging (rma) algo-
rithm in the Bioconductor package affy (see http://www.
bioconductor.org/) in order to obtain summary expression
values for each probe set [9,10]. This resulted in more
than 17,000 genes, each of which then has one numeric
number to represent its relative gene expression intensity
in the sample.
Clustering study
A hierarchical clustering algorithm was used to identify
unsupervised clusters based on the Euclidean distance
for dissimilarities between the data samples. The slightly
modified “plot.phylo” program from analyses of phyloge-
netics and evolution (ape) package of R was used to
show the clustering results [11,12]. The interquartile
range (IQR) and coefficient of variation (CV) were used
to filter identified genes in the unsupervised clustering
study. IQR was defined to be the distance between theFigure 2 Boxplot of the 27 samples used for study presented in log2third and first quartiles of the data; the CV of a vector
was defined to be the standard deviation divided by its
mean value. We used IQR > 0.3 and CV > 0.05 as our
filtering criteria. This resulted in a data set of approxi-
mately 13600 genes. Other cutoff values provided similar
clustering results. We also used the limma package to
identify genes for supervised clustering analysis. When
more than two classes of genes were present in the study
group, the comparison was made between all pairs of
classes. When comparison was made between two con-
ditions, we used a fold change of 5 as a cutoff value to
declare a gene significant.
We set 0.05 as our significance level for all tests.
All calculations were implemented in R environment
(R > 2.15.0, see http://www.r-project.org).
Results
Comparative analysis
Despite the shared urothelium from which SCCa and
UCa arises, it is unclear whether these two morphologic-
ally distinct forms of bladder cancer share significant
molecular overlap and, if so, whether a hierarchy in
tumor types exists. In order to address this question, we
performed a four-way interrogation of gene expression
profiles: 1) normal urothelium versus SCCa, 2) normal
urothelium versus UCa, 3) normal urothelium versus
SCCa and UCa combined (shared alterations) and 4)
UCa versus SCCa (divergent alterations). We included
for analysis 8 samples of normal urothelium, 10 samples
of invasive high-grade UCa and 9 samples of invasive
SCCa. A boxplot of the data set shows that all samples
have a roughly comparable distribution of the gene ex-
pression values, except only one sample (normal sample
1; Figure 2). When analyzed by subsequent unsupervised
or supervised clustering studies, sample 1 did correctly
segregate into the normal urothelial cluster; we therefore
retained this sample in our study set.
Unexpectedly, the gene expression profiles revealed a
large number of shared gene expression differences inscale.
Figure 3 Heatmap comparing UCa and SCCa to normal urothelium for all 27 samples using supervised clustering and a fold change of
5, with 262 genes represented.
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using a 5-fold cut-off (n = 137, Figure 3). In addition to
these shared gene expression differences, SCCa demon-
strated an additional 366 uniquely dysregulated genes
relative to normal urothelium, whereas UCa demon-
strated only an additional 18 genes that were uniquelyFigure 4 Supervised clustering of the 27 samples using the top
most significant 877 genes (limma method from Bioconductor
using adjusted p value <=0.001; error rate 1/27=3.7%; black =
UCa; red = SCCa; green = normal).dysregulated relative to normal urothelium. Using super-
vised clustering (Figure 4) and unsupervised clustering
(Figure 5A, B) analysis, we were able to reproducibly
segregate normal urothelium, UCa and SCCa specimens,
although two specimens (UCa23 and UCa24) appeared
slightly different than other tumors in the UCa category,
but could correctly segregate with other UCa specimens
when a lower threshold value was applied to the analysis;
specifically, no morphological difference was appreciated
in these two specimens.
All differentially expressed genes were used to obtain
fold changes (in log2 scale) to compare UCa versus nor-
mal and SCCa versus normal (Figure 6A). The majority
of genes have fold change differences within 2 (17,468,
99.25%, grey). A relatively larger number of genes have
fold change differences above 2 (184, red) than the num-
ber of genes with fold change differences below −2 (47,
blue). Overall, the fold change vectors correlated well
with each other (cor. coefficient greater than 0.73), with
the exception of the 184 genes located above the se-
lected area (red), which are significantly higher in SCCa
when compared to normal urothelium. A summary of
the 4-way analysis performed with total gene expression
differences is presented in Figure 6B.
Commonly dysregulated genes in UCa and SCCa versus
normal urothelium
We next sought to determine commonalities in gene ex-
pression changes in UCa and SCCa versus normal
urothelium. As normal urothelium lines the urinary tract
throughout its length, and represents the common epi-
thelium from which any form of bladder cancer (with
Figure 5 Unsupervised clustering analysis using approximately
4500 genes filtered first by the interquantile range (IQR, >0.3)
then by the coefficient of variation (CV, >0.05) resulted in an
error rate of 2/27=7.4% (black = UCa; red = SCCa; green =
normal) represented as (A) dendrogram and (B)
phylogram (unrooted).
Figure 6 Significantly differentially expressed genes between
UCa and SCCa versus normal samples represented as (A)
scatterplot comparing fold change (FC) differences between
UCa versus normal samples and SCCa versus normal samples
(98.7% of genes have FC ≤2, correlation coefficient=0.73) and
(B) Venn diagram with FC cutoff value=5.
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whether shared pathways were commonly altered in
these forms of bladder cancer. Using this rationale, we
identified 137 genes that differed by at least 5-fold in
cancer specimens relative to normal urothelium (45
upregulated and 92 downregulated genes), with a repre-
sentative subset containing functions related to cell
growth and/or reported in cancer listed in Table 1.
The mitotic spindle checkpoint appeared generally
upregulated, with overexpression of gene products of
aurora kinase A (AURKA), aurora kinase B (AURKB),
BUB1B, NUF2, MAD2L1, CCNB1,TPX2, ZWINT, ZWINTand CDC20. Although these genes may be upregulated
simply due to increased proliferative capacity of carcin-
omas, aurora kinase A has been previously investigated in
UCa, where it is commonly found to be amplified [13] and
may be a potential novel therapeutic target [14], which
validates our results. A second category of upregulated
genes included nicotine-responsive genes, as identified in
both lung and head and neck squamous cancers, and
include TTK, CEP55, PRC1 and FOXM1 [15-18]. As to-
bacco smoking is a preeminent risk factor for the develop-
ment of both UCa and SCCa of the bladder, these genes
may reflect this association. An additional category of
overrepresented gene products included putative stem cell
markers and/or mediators encoded by TTK, MELK,
DLG7, and PBK [19-22]. Of note, very few pro-migratory
factors were found to be upregulated in this shared popu-
lation with the most likely pro-migration factor repre-
sented by RACGAP1, which encodes a small RhoGTPase.
Downregulated genes grouped into the major categories
of inflammatory mediators [23], nicotine metabolizing
genes, regulators or apoptosis and cell adhesion factors.
Downregulated gene products include CFD, C7, DARC,
PTX3, CD302, HLA-DQA1, CD69, P2RY14, SELE, JAM2,
and CCL14, which include mediators of inflammatory cell
Table 1 Commonly dysregulated genes shared by urothelial and squamous carcinoma versus normal rothelium
Gene Fold change UCa Fold change SCCa Function
UBE2C 15.1 15.1 Ubiquitin-conjugating enzyme; promotes cell cycle; amplified in UCC
TOP2A 13 14.8 DNA topoisomerase
CDC20 11.4 21.1 Regulates RUNX1; interacts with Aurora A; cell cycle regulation
CCNB2 9.49 12.5 Cyclin B2; TGF-beta mediated cell cyle control
CEP55 9.32 15.1 Centromeric protein regulated by FOXM1
TPX2 9.32 11.6 Microtubule formation at kinetochores
TTK 9.08 10.7 Mitotic spindle checkpoint protein; smoking responsive gene
FOXM1 8.99 7.66 Can increase levels of cyclin family members; smoking responsive gene
ZWINT 8.87 7.37 Kinetochore interactor
BUB1B 8.83 9.06 Kinase involved in spindle checkpoint function
MELK 8.58 12.4 AMPK related kinase; implicated in stem cell function
DLG7 7.98 12.3 Putative stem cell factor that interacts with kinetochore; increased in UCC
NUF2 7.64 7.97 Kinetochore-associated protein involved in chromosome segregation
MAD2L1 7.61 9.06 Spindle checkpoint protein; regulates start of anaphase
AURKB 6.62 9.53 Microtubule-associated protein involved in chromosome segregation
CCNB1 6.43 9.89 Cyclin B1; complexes with p34 to regulate mitotic activity
RACGAP1 6.24 5.89 RhoGTPase encoding gene
AURKA 5.64 8.51 Kinetochore-associated protein found at spindle poles during mitosis
ADH1B −42.3 −70.1 Involved in tobacco smoke detoxification; implicated in esophageal cancer
UPK1A −14.4 −22.4 Urothelium-associated protein
FHL1 −12.5 −8.37 LIM-protein that regulates apoptosis and proliferation
ANXA10 −12.1 −18.8 Regulates cell growth; synergizes with p53 mutation for worse outcomes
ADAMTS1 −10.0 −8.56 Matrix metalloproteinase
DARC −9.93 −15.9 Binds cytokines; can influence tumor cell binding to endothelial cells
MYH11 −8.96 −18.8 Smooth muscle myosin
DMN −8.81 −11.0 Intermediate filament associated with desmin
TCF21 −7.43 −9.92 Tumor suppressor gene; undergoes methylation in some cancers
HLA-DQA1 −7.01 −8.38 Expression may be altered following repeated BCG exposure
CD69 −6.63 −5.48 Lectin superfamily; reduced in head and neck SCC patients
ANK2 −6.28 −8.84 Links integral membrane proteins to the underlying cytoskeleton
CLU −6.18 −5.72 Apoptotic mediators; expression decreased in many cancers
SELE −6.14 −7.75 Inflammatory mediator; regulates immune cell-endothelial interaction
JAM2 −6.07 −7.61 Tight junction protein; regulates immune cell binding
AOX1 −5.76 −7.12 Nicotine metabolizing protein
PROM1 −5.27 −8.29 Expressed in adult stem cells; mediates differentiation
CCL14 −5.09 −8.40 Cytokine
Differentially expressed genes have an adjusted p value of <0.05.
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DQ1 has been evaluated previously in UCa and its expres-
sion is associated with repeated exposure (and response)
to BCG [24].
ADH1B and AOX1 are involved in the metabolism of
nicotine, with the former gene implicated in the risk of
esophageal carcinoma [25]. Apoptotic mediators that are
downregulated include CLU, FHL1 and PCP4, whereascell adhesion and cytoskeletal mediators that are down-
regulated include UPK1A, MYH11, DMN, MFAP4, ITM2A,
ANK2, JAM2,MYLK, PROM1, DPT, and FBLN5.
Of the 137 genes differentially expressed between
bladder UCa and SCCa versus normal urothelium, 18
have been previously reported to be up/down regulated
in UCa and 35 have been reported in SCCa arising from
non-bladder sites. Due to the rarity of profiling papers
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not been studied in this entity to date.
A limited subset of uniquely dysregulated genes defines
UCa
One of the most surprising results from this study are the
very small number of genes that were found to be
uniquely dysregulated in UCa versus normal urothelium
(n = 18; representative subset Table 2). The remainder of
dysregulated genes (n = 137) are found in common with
those altered in bladder SCCa. Uniquely dysregulated
genes in UCa include CLCA4 (chloride channel), IL33,
GPR171 (G protein coupled receptor), CENPF (centro-
mere protein F) and CD36 (thrombospondin receptor).
EZH2 has been reported to be upregulated in UCa and
represents a putative stem cell marker [26] and a repressor
of E-cadherin expression [27]; of relevance, E-cadherin is
frequently lost in high-grade UCa [28].
Well-categorized squamous factors are uniquely
upregulated in SCCa
Finally, we analyzed uniquely dysregulated genes in SCCa
versus normal urothelium and identified 185 upregulated
and 181 downregulated unique genes that differed by at
least 5-fold between these two groups (representative sub-
set presented in Table 3). The majority of dysregulated
genes are factors that have been associated with the squa-
mous phenotype and histology, with many of these factors
identified in squamous carcinomas arising at other sites.
Upregulated gene products include keratins that areTable 2 Uniquely dysregulated genes in grothelial garcinoma
Gene Fold change UCa Function
MEST 8.14 Encodes a me
EZH2 5.57 Stem cell relat
CENPF 5.54 Component o
GINS2 5.43 Psf2 homolog
CLCA4 −11.9 Member of th
POU2AF1 −8.96 Regulates TH1
IL33 −7.99 Member of IL1
SEPP1 −6.94 Selenoprotein
IL6 −6.57 Inflammatory
GPR171 −6.45 G protein-cou
FOSB −6.26 One member
ITK −6.05 Regulator of T
AGR3 −5.62 May regulate p
CCL19 −5.45 Cytokine affec
CD36 −5.42 Thrombospon
DKK1 −5.33 Inhibits WNT s
Differentially expressed genes have an adjusted p value of <0.05.specific for squamous epithelium (KRT6B, KRT16, KRT5,
KRT20), the family of S100 calcium binding proteins com-
monly upregulated in SCCa from various anatomical sites
(S100A7, S100A8, S100A9, S100A12, S100A14, S100A16),
the serpin family (SERPINB1-7), desmosome-associated
proteins that characterize squamous epithelium (DSG1,
DSG3, PKP1, PKP3), numerous peptides (PI3, SPINK5,
KLK7, SLPI), and a variety of pro-motility factors. Down-
regulated gene products include putative tumor suppres-
sor genes (SCUBE2), factors previously reported as lost in
aggressive bladder cancer (FOXA1, GATA3, UPK3A), and
metabolizing enzymes with polymorphisms affecting can-
cer risk (UGT1A10, UGT1A7).
Discussion
Current pathological classification distinguishes UCa and
SCCa as distinct diagnostic entities [4]. This has resulted
in numerous publications that have evaluated the differ-
ences in clinical outcomes, treatment response and mo-
lecular profiles that distinguish these two bladder cancer
types, with mixed results [29]. Although some studies
have suggested that when compared stage-for-stage, the
outcomes are similar for patients with bladder UCa and
SCCa [3,29,30], other studies have implicated that SCCa
and/or UCa with squamous differentiation may present at
a higher stage and behave more aggressively [31-33]. One
consistency amongst studies is the limited response of
bladder SCCa of the bladder to conventional chemother-
apy and/or radiation therapy that is administered in the
setting of UCa and may relate to the squamous phenotypeversus normal urothelium
mber of alpha/beta hydrolase superfamily; imprinting in cancer
ed gene; previously reported as upregulated in UCa
f centromere/kinetochore complex; affects chromosome segregation
; complex component that regulates DNA replication in yeast
e calcium sensitive chloride conductance superfamily
and TH2 immune responses
family; enhances TH2 cytokine production
; may affect oxidative stress response
cytokine; increased after BCG administration in the bladder
pled receptor; may regulate hematopoietic progenitor cells
of the AP-1 transcription factor complex; implicated in ovarian carcinoma
cell proliferation
rotein folding; may regulate cisplatin resistance in ovarian cancer
ting B and T cell migration; may enhance B-cell mediated immunity;
din receptor; may affect tumor vascularity and matrix content
ignaling; may inhibit invasive behavior and self-renewal in some cancers
Table 3 Uniquely dysregulated genes in squamous cell carcinoma versus normal urothelium
Gene Fold change SCCa Function
KRT6B 289 High molecular weight cytokeratin; stratified epithelium differentiation
S100A7 242 Promotes migration and invasion of SCCa; reported in urine of bladder SCCa patients
KRT16 147 High molecular weight cytokeratin
PI3 140 Peptidase inhibitor 3/elafin; marker of abnormal squamous growth; induced by inflammation
DSG3 77.6 Desmosome-associated protein; upregulated in
various forms of SCCa
SERPINB4 58.3 Member of human SCCa antigen locus; activated by STAT3; enhances survival of SCCa cells
CNFN 56.3 Cornifelin; squamous epithelial marker
KLK10 53.9 Serine protease; increased in oral and lung SCCa
SERPINB3 42.5 Member of human SCCa antigen locus; activated by STAT3; enhances survival of SCCa cells
FGFBP1 31.3 FGF carrier protein; promotes angiogenesis in SCCa from various sites
MMP1 31.0 Matrix metalloproteinase that degrades collagens; induced by EGF in bladder cancer patients
DSG1 29.6 Desmosome-associated protein; enhances loss of cell adhesion in SCCa from various sites
KRT5 25.8 High-molecular weight cytokeratin; expressed by squamous epithelium
DSC3 25.1 Desmosome-associated protein; marker of squamous differentiation; can
inhibit EGFR pathway
S100A8 22.9 May predict metastatic potential of bladder cancer; increased in SCCa from various sites
LY6D 21.1 Affects interaction between SCCa cells and endothelial cells
CA2 19.3 Carbonic anhydrase II; Previously reported in bladder SCCa
MMP10 18.7 Matrix metalloproteinase; activated by EGF and STAT3; inhances SCCa invasion at other sites
PTHLH 15.5 Parathyroid hormone-like hormone; previously reported in bladder SCCa; may affect apoptosis
SCEL 15.1 Squamous epithelium marker
CALB1 12.9 Calbindin 1; calcium binding protein of the troponin C superfamily
PTPRZ1 11.9 Receptor protein tyrosine phosphatase; involved in CNS development
LAMC2 8.95 Laminin, gamma2; Overexpressed in esophageal SCC
KIF14 6.58 Microtubule motor protein; reported in laryngeal carcinoma
JUP 6.31 Associated with both desmosomes and intermediate junctions
SCUBE2 −27.1 Secreted protein; putative tumor suppressor in breast cancer
HPGD −20.6 Metabolism of prostaglandins; downregulated in gastric cancer by COX2
HMGCS2 −15.6 HMG-CoA synthase family; enzyme involved in ketogenesis
CYP4B1 −15.0 Involved in drug metabolism and lipid synthesis; related to bladder cancer risk in one study
TGFBR3 −13.1 Encodes TGF-β receptor III; reduced expression in numerous cancers
UPK3A −10.9 Uroplakin 3A; urothelial marker; loss of expression associated with aggressive bladder cancer
AOC3 −10.1 Copper amine oxidase; aids in leukocyte adhesion and transmigration
FBLN1 −9.86 Secreted glycoprotein; may be involved in ECM remodeling; downregulated in gastric cancer
FOXA1 −9.82 Forkhead class of DNA binding proteins; loss occurs in aggressive bladder cancer
PPARG −9.27 Regulate gene transcription together with retinoid X receptors; may
influence BCG response
GATA3 −8.97 Transcription factor; downregulated in bladder cancer
CCL15 −8.63 Chemotactic for T cells and monocytes;
TSPAN8 −7.96 Tetraspanin family; interacts with integrins; may regulate motility in various cancers
ADRA2A −7.75 Alpha-2-adrenergic receptor;
PDGFD −7.74 PDGF family; can regulate motility in many cancer types and
chemotaxis
KRT20 −6.32 Low molecular weight cytokeratin; typically patchy expression in urothelial carcinoma
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Table 3 Uniquely dysregulated genes in squamous cell carcinoma versus normal urothelium (Continued)
CYP1A1 −5.7 Hypermethylated in bladder cancer; polymorphisms related to bladder
cancer risk
CYP1B1 −5.61 Polymorphisms associated with bladder cancer risk
UGT1A10 −5.28 UDP-glucuronosyltransferase; involved in detoxification of carcinogens
UGT1A7 −5.28 UDP-glucuronosyltransferase; polymorphisms associated with cancer risk
Differentially expressed genes have an adjusted p value of <0.05.
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two forms of bladder cancer that arise from the urothelial
lining of the bladder has not been clearly delineated.
The results from our study suggest that UCa generally
shares the majority of its dysregulated genes relative to
normal urothelium in common with SCCa, with very
few uniquely dysregulated genes; in contrast, SCCa –
while sharing many genes in common with UCa – shows
a much larger category of dysregulated genes that are
often in common with SCCa arising at other sites. When
considering the relationship between these two closely
related entities, two possibilities emerge. First, invasive
UCa may represent a default pathway of bladder cancer
development, with clonal change resulting in SCCa de-
velopment and overgrowth of a pre-existent UCa. This
hypothesis is supported by the not infrequent finding
of mixed morphology bladder cancers, where a well-
documented UCa contains areas of squamous and/or
glandular differentiation [4]. Further supporting this
hypothesis is a prior paper that has examined the rela-
tionship of co-existent small cell carcinoma and UCa of
the bladder: the results from this prior study suggest that
the small cell carcinoma in this setting represented a
clonal outgrowth from the background invasive UCa
[36] a finding that might not be dissimilar across all
other bladder cancer “subtypes” and which can be sup-
ported by the findings in this paper. A second possibility
is that an early bladder cancer stem cell exists, either
prior to invasion or early in the course of invasion,
which gives rise to distinct morphological entities along
discrete molecular lineages that are considered pure sub-
types. Specifically, early molecular changes define a
number of shared alterations between various bladder
cancer subtypes that subsequently diverge along differ-
ent morphologic lines [36]. In such a scenario, the lim-
ited number of additional alterations identified in UCa
would suggest this to be a “default” pathway in bladder
carcinogenesis, with significant additional alterations re-
quired to develop the squamous phenotype.
Regardless of the model proposed, the current data sup-
ports a close evolution between UCa and SCCa, with gene
expression changes in the latter primarily reflecting mor-
phological correlates of the squamous phenotype seen in
SCCa arising from different sites. Our data also suggest
that proliferative changes, including deregulation (and insome cases amplification) of mitotic spindle checkpoint
components may be critical in the early stages of bladder
tumorigenesis. Further validation of our findings using
other “pure” types of bladder cancer – such as adenocar-
cinoma and small cell carcinoma – will further strengthen
the implications of our results, although the rare nature of
these other forms of bladder cancer may make such a
study challenging.
Although we have used only one technique to analyze
the relationship between UCa and SCCa, our ability to
reproducibly segregate the entities in our study using
both supervised and unsupervised clustering analysis
suggest that our data is robust. A second limitation is
the use of a limited number of specimens for analysis,
although the use of 10 SCCa samples is relatively high
given the rarity of this disease entity. The overall gene
expression profiles between our two bladder cancer
entities suggest that the development of these bladder
cancer forms occurs along similar lines. However, it is
clear that the magnitude of expression changes differs in
some instances; for example, reduction in ADH1B oc-
curs by a factor of 40-fold in UCa and 70-fold in SCCa.
The importance of relative fold change (versus direction-
ality) in these cancer subtypes was not a primary focus
of investigation in this study. However, the relative
increase or decrease in mRNA expression may have a
relevant biological role when studied in a whole cell
system.
Our study has identified numerous categories of genes
that may be of relevance to the development of UCa,
including mitotic spindle regulators, putative stem cell
factors, nicotine metabolizing enzymes and inflamma-
tory regulators. The vast majority of these genes appear
to be similarly dysregulated in bladder SCCa. One ex-
ception is a large category of inflammatory mediators
(POU2AF1, IL33, IL6, ITK, CCL19) that are altered and
may reflect the administration of BCG, which is fre-
quently given intravesically for superficial UCa but not
SCCa. In contrast, SCCa appears to overlap significantly
in gene expression differences with UCa and additionally
contains a large number of additional up- and down-
regulated gene products. Perhaps not surprisingly, many
of these gene transcripts have been reported in SCCa
from the head and neck region, oral cavity, lung and
skin. As SCCa is considered to have limited response to
Hansel et al. BMC Medical Genomics 2013, 6:42 Page 10 of 11
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list of discrete targets – some of which are currently
undergoing clinical trials for targeted therapy in other
forms of SCCa – may provide an alternative treatment
for patients with either pure or mixed SCCa of the
bladder.
Conclusions
In summary, we found that UCa and SCCa of the blad-
der share a number of differentially regulated genes,
suggesting a close evolution of these two major subtypes
of bladder cancer. Future studies that seek to further
delineate the relationship and, thus, pathogenesis of vari-
ous forms of bladder cancer will provide additional
insight into the development of bladder cancer. Ultim-
ately, the finding of shared molecular changes may allow
investigators to develop targeted therapy that may be
used either earlier in the course of disease or treat a
broader range of cancer morphologies with success.
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